Studieoverzicht - 2008-02 A6181099
Principal Investigator(s) | A.H. Honkoop | |||
Study manager | ||||
Central datamanagement and randomization | ||||
Monitoring | Pfizer | |||
Local datamanagement | ||||
Funding | ||||
Extra |
Design:
Objectives:
Endpoints:
Primary enpoint:
- Progression Free Survival
Secondary enpoints:
- Overall response rate
- Duration of response
- Overall survival
- Two- and 3-year survival
- Quality of life.
Main eligibility criteria:
- Metastatic or locally advanced breast cancer
- Measurable disease or botmetastasis only
- Pre treatment with anthracyclines and taxane
- Her2 positive and negative
- >18 years
Documents (public):
Back